EPHB6, EPH receptor B6, 2051

N. diseases: 60; N. variants: 1
Disease: Neoplasm Metastasis ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.080 AlteredExpression phenotype BEFREE Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression. 28826721 2017
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.080 Biomarker phenotype BEFREE Loss of the EPH receptor B6 contributes to colorectal cancer metastasis. 28262839 2017
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.080 Biomarker phenotype BEFREE Analytic results based on pathological parameters suggests that EphB6 protein may inhibit metastasis of gastric carcinoma and could be a potential therapeutic target for gastric carcinoma. 28453458 2017
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.080 GeneticVariation phenotype BEFREE The biological functions and representative deregulated genes include cell proliferation (AIM2, FAP, TNFSF13B, TMPRSS11A); signal transduction (FOLR2, MME, HTR3B); invasion and metastasis (SPP1, TNFAIP6, EPHB6); differentiation (CLEC4A, ELF5); angiogenesis (CXCL1); apoptosis (GLIPR1, WISP1, DAPL1); and immune responses (CD300A, IFIT2, TREM2); and metabolism (NNMT; ALDH3A1). 25663065 2015
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.080 Biomarker phenotype BEFREE Furthermore, EphB6-expressing melanoma cells display significantly reduced metastatic potential in a chorioallantoic membrane (CAM) metastasis assay. 24836890 2014
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.080 GeneticVariation phenotype BEFREE Our results suggest that EPHB6 mutations promote metastasis in a subset of patients with non-small cell lung cancer. 23226491 2012
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.080 AlteredExpression phenotype BEFREE Decreased EPHB6 expression levels were associated with an increased risk for metastasis development in NSCLC patients. 20371680 2010
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.080 AlteredExpression phenotype BEFREE Decreased expression levels of EPHB6, a member of the receptor tyrosine kinases (RTKs), are associated with an increased risk of metastasis development in early stage non-small cell lung cancer (NSCLC). 19513565 2009